A Peripherally Acting Nav1.7 Sodium Channel Blocker Reverses Hyperalgesia and Allodynia on Rat Models of Inflammatory and Neuropathic Pain

200960 citationsJournal Article

Authors

Erin McGowan · Merck & Co., Inc., Rahway, NJ, USA (United States)

Scott B. Hoyt · Merck & Co., Inc., Rahway, NJ, USA (United States)

Xiaohua Li · Merck & Co., Inc., Rahway, NJ, USA (United States)

Kathryn A. Lyons · Merck & Co., Inc., Rahway, NJ, USA (United States)

Catherine Abbadie · Merck & Co., Inc., Rahway, NJ, USA (United States)

Abstract

These data suggest that a peripherally acting sodium channel blocker, preferentially acting through Na(v)1.7, could provide clinical relief of chronic pain without the CNS side effects typical of many existing pain treatments.

Topics & Keywords

Pain Mechanisms and Treatments Ion channel regulation and function Neuroscience and Neuropharmacology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Anesthesia & Analgesia

Volume 109, Issue 3, pp. 951-958

DOI: 10.1213/ane.0b013e3181b01b02

Field-Weighted Citation Impact: 3.21